Dr Munshi on the Background of the CARTITUDE-1 Trial in Multiple Myeloma

Nikhil C. Munshi, MD, discusses the background of the phase 1b/2 CARTITUDE-1 trial of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma and highlights the specific patient population enrolled in the study.

Related Keywords

Nikhilc Munshi , ,Dana Farber Cancer Institute ,Medicine At Harvard Medical School ,Correlative Science ,Jerome Lipper Multiple Myeloma Center ,Kraft Family Chair ,Multiple Myeloma Immune Effector Cell Therapy ,Harvard Medical School ,Multiple Myeloma ,Onclive Tv ,